|
Sections |
| Title | Starting Page | Number of Pages |
|---|
| CHAPTER GLOBAL MARKET ANALYSIS | 1 | 2 |
| 1.1 ANTI-ASTHMATIC MARKET ANALYSIS BY DRUG CLASS | 2 | 1 |
| OVERVIEW OF GLOBAL ANTI-ASTHMATIC MARKET | 2 | 3 |
| TABLE1: GLOBAL SALES IN THE ANTI-ASTHMATIC MARKET BY DRUG CLASS, 1999-2000 | 2 | 1 |
| KEY TRENDS IN THE GLOBAL ASTHMA MARKET | 5 | 2 |
| TABLE2: SALES GROWTH IN THE GLOBAL ANTI-ASTHMATIC MARKET BY DRUG CLASS, 1996-2000 | 5 | 1 |
| 1.2 BETA2 AGONISTS | 8 | 1 |
| TABLE3: BETA2-AGONIST FACT FILE | 8 | 1 |
| OVERVIEW OF THE GLOBAL BETA2(-) AGONIST MARKET | 8 | 3 |
| TABLE4: GLOBAL SALES OF THE LEADING BRANDED BETA2(-) AGONIST DRUGS, 1999- 2000 | 8 | 1 |
| Key product sales in 2001 | 10 | 1 |
| TABLE5: KEY BETA2(-) AGONIST PRODUCT SALES, 2001 | 10 | 1 |
| KEY TRENDS IN THE GLOBAL BETA2(-) AGONIST MARKET | 11 | 1 |
| TABLE6: SALES GROWTH IN THE BETA2(-) AGONIST MARKET, 1996-2000 | 11 | 1 |
| COMPARISON OF KEY BRANDS IN BETA2(-) AGONIST CLASS | 12 | 1 |
| TABLE7: SUMMARY OF LEADING BETA2(-) AGONIST DRUGSWOTANALYSES | 13 | 1 |
| SEREVENT (SALMETEROL) | 14 | 1 |
| TABLE8: SEREVENT:KEY FACTS | 14 | 1 |
| Drug overview | 14 | 1 |
| Cross-indication and reformulation | 15 | 1 |
| SWOT analysis | 16 | 1 |
| VENTOLIN (ALBUTEROL) | 17 | 1 |
| TABLE9: VENTOLIN:KEY FACTS | 17 | 1 |
| Drug overview | 17 | 1 |
| Reformulation and cross-indication | 18 | 1 |
| SWOT analysis | 19 | 1 |
| FORADIL (FORMOTEROL) | 20 | 1 |
| TABLE10: FORADIL:KEY FACTS | 20 | 1 |
| Drug overview | 20 | 1 |
| Approval in the US | 21 | 1 |
| SWOT analysis | 21 | 1 |
| OXIS (FORMOTEROL) | 22 | 1 |
| TABLE11: OXIS:KEY FACTS | 22 | 1 |
| Drug overview | 22 | 1 |
| Drivers of future growth | 23 | 1 |
| SWOT analysis | 24 | 1 |
| 1.3 CORTICOSTEROIDS | 25 | 1 |
| TABLE12: CORTICOSTEROIDS FACT FILE | 25 | 1 |
| OVERVIEW OF THE GLOBAL CORTICOSTEROID MARKET | 26 | 2 |
| TABLE13: GLOBAL SALES OF THE LEADING BRANDED CORTICOSTEROID DRUGS, 1999-2000 | 26 | 1 |
| Key product sales in 2001 | 27 | 1 |
| TABLE14: KEY CORTICOSTEROID PRODUCT SALES, 2001 | 28 | 1 |
| KEY TRENDS IN THE GLOBAL CORTICOSTEROID MARKET | 28 | 2 |
| TABLE15: SALES GROWTH IN THE CORTICOSTEROID MARKET, 1996-2000 | 28 | 1 |
| COMPARISON OF KEY BRANDS IN THE CORTICOSTEROID CLASS | 30 | 1 |
| TABLE16: SUMMARY OF LEADING CORTICOSTEROID DRUGSWOTANALYSES | 30 | 1 |
| FLOVENT (FLUTICASONE) | 31 | 1 |
| TABLE17: FLOVENT:KEY FACTS | 31 | 1 |
| Drug overview | 31 | 1 |
| Line extensions: Cross-indication | 32 | 1 |
| Line extensions: Reformulation | 32 | 1 |
| Patent expiry | 33 | 1 |
| SWOT analysis | 33 | 1 |
| PULMICORT (BUDESONIDE) | 34 | 1 |
| TABLE18: PULMICORT:KEY FACTS | 34 | 1 |
| Drug overview | 34 | 1 |
| Growth driver: Pulmicort Respules | 35 | 1 |
| Extending patent protection | 35 | 1 |
| SWOT analysis | 36 | 1 |
| 1.4 COMBINATION PRODUCTS | 37 | 1 |
| TABLE19: COMBINATION PRODUCTS FACT FILE | 37 | 1 |
| OVERVIEW OF THE GLOBAL COMBINATION PRODUCT MARKET | 37 | 2 |
| TABLE20: GLOBAL SALES OF THE LEADING BRANDED COMBINATION PRODUCT DRUGS, 1999-2000 | 37 | 1 |
| Key product sales in 2001 | 38 | 1 |
| TABLE21: KEY COMBINATION PRODUCT SALES, 2001 | 38 | 1 |
| COMPARISON OF KEY BRANDS IN THE COMBINATION PRODUCT CLASS | 39 | 1 |
| TABLE22: SUMMARY OF LEADING COMBINATION PRODUCTSWOTANALYSES | 39 | 1 |
| ADVAIR (SALMETEROL&FLUTICASONE) | 40 | 1 |
| TABLE23: ADVAIR:KEY FACTS | 40 | 1 |
| Drug overview | 40 | 1 |
| Advair performance in 2001 | 41 | 1 |
| Future drivers of growth | 41 | 1 |
| SWOT analysis | 42 | 1 |
| SYMBICORT (FORMOTEROL&BUDESONIDE) | 43 | 1 |
| TABLE24: SYMBICORT:KEY FACTS | 43 | 1 |
| Drug overview | 43 | 1 |
| Key clinical trials | 44 | 2 |
| SWOT analysis | 46 | 1 |
| 1.5 LEUKOTRIENE ANTAGONISTS | 47 | 1 |
| TABLE25: LEUKOTRIENE ANTAGONIST FACT FILE | 47 | 1 |
| OVERVIEW OF THE GLOBAL LEUKOTRIENE ANTAGONIST MARKET | 47 | 2 |
| TABLE26: GLOBAL SALES OF THE LEADING BRANDED LEUKOTRIENE ANTAGONIST DRUGS, 1999-2000 | 47 | 1 |
| KEY TRENDS IN THE GLOBAL LEUKOTRIENE ANTAGONIST MARKET | 49 | 2 |
| TABLE27: SALES GROWTH IN THE LEUKOTRIENE ANTAGONIST MARKET, 1996-2000 | 49 | 1 |
| Key product sales in 2001 | 50 | 1 |
| TABLE28: KEY LEUKOTRIENE ANTAGONIST PRODUCT SALES, 2001 | 50 | 1 |
| COMPARISON OF KEY BRANDS IN LEUKOTRIENE ANTAGONIST CLASS | 51 | 1 |
| TABLE29: SUMMARY OF LEADING LEUKOTRIENE ANTAGONIST PRODUCTSWOT ANALYSES | 51 | 1 |
| SINGULAIR (MONTELUKAST) | 52 | 1 |
| TABLE30: SINGULAIR:KEY FACTS | 52 | 1 |
| Drug overview | 52 | 1 |
| Future drivers of growth | 53 | 1 |
| SWOT analysis | 54 | 1 |
| ACCOLATE (ZAFIRLUKAST) | 55 | 1 |
| TABLE31: ACCOLATE:KEY FACTS | 55 | 1 |
| Drug overview | 55 | 1 |
| SWOT analysis | 56 | 1 |
| 1.6 ANTICHOLINERGICS | 57 | 1 |
| TABLE32: ANTICHOLINERGICS FACT FILE | 57 | 1 |
| OVERVIEW OF THE GLOBAL ANTICHOLINERGIC MARKET | 57 | 2 |
| TABLE33: GLOBAL SALES OF THE LEADING BRANDED ANTICHOLINERGIC DRUGS, 1999-2000 | 57 | 1 |
| KEY TRENDS IN THE GLOBAL ANTICHOLINERGIC MARKET | 58 | 1 |
| TABLE34: SALES GROWTH IN THE ANTICHOLINERGIC MARKET, 1996-2000 | 58 | 1 |
| COMPARISON OF KEY BRANDS IN THE ANTICHOLINERGIC CLASS | 59 | 1 |
| TABLE35: SUMMARY OF LEADING ANTICHOLINERGIC PRODUCTSWOTANALYSES | 59 | 1 |
| 1.7 RESPIRATORYNSAIDS | 60 | 1 |
| TABLE36: RESPIRATORYNSAIDS FACT FILE | 60 | 1 |
| OVERVIEW OF THE GLOBAL RESPIRATORYNSAIDS MARKET | 60 | 2 |
| TABLE37: GLOBAL SALES OF THE LEADING BRANDED RESPIRATORY NSAIDS, 1999-2000 | 60 | 1 |
| KEY TRENDS IN THE GLOBAL RESPIRATORYNSAIDS MARKET | 62 | 1 |
| TABLE38: SALES GROWTH IN THE RESPIRATORYNSAIDS MARKET, 1996- 2000 | 62 | 1 |
| COMPARISON OF KEY BRANDS IN THE RESPIRATORYNSAIDS CLASS | 64 | 1 |
| TABLE39: SUMMARY OF LEADING RESPIRATORYNSAIDSSWOTANALYSES | 64 | 1 |
| 1.8 XANTHINES | 65 | 1 |
| TABLE40: XANTHINE FACT FILE | 65 | 1 |
| OVERVIEW OF THE GLOBAL XANTHINE MARKET | 65 | 2 |
| TABLE41: GLOBAL SALES OF THE LEADING BRANDED XANTHINE DRUGS, 1999-2000 | 65 | 1 |
| KEY TRENDS IN THE GLOBAL XANTHINE MARKET | 67 | 1 |
| TABLE42: SALES GROWTH IN THE XANTHINE MARKET, 1996-2000 | 67 | 1 |
| COMPARISON OF KEY BRANDS IN THE XANTHINE CLASS | 68 | 1 |
| TABLE43: SUMMARY OF LEADING XANTHINESWOTANALYSES | 68 | 1 |
